MXCT vs TFX · rev $38.6M vs P/E 2083, rev $3.05B
MaxCyte Inc (MXCT) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TFX revenue for 2024-12-31 was $3.05B. Net income was $69.7M. Revenue was up 2.4% from 2023-12-31 to 2024-12-31. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
MXCT currently screens at market cap $124.3M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the MXCT and TFX stock pages for the full models.
Not investment advice.